Medical device maker Boston Scientific Corp. (BSX) announced that the U.S. District Court for the District of New Jersey has found all the asserted patents in a suit brought by Healthcare giant Johnson & Johnson (JNJ) to be invalid and entered judgment in favor of Boston Scientific.
Under the 2008 patent infringement suit, Johnson & Johnson alleged that Boston Scientific's PROMUS Everolimus-Eluting Coronary Stent System infringed two patents, U.S. Patent Nos. 5,516,781 and 5,563,146. The patents relate to the use of a drug on a drug-eluting stent.
For comments and feedback: editorial@rttnews.com